Dr. Robert M. Ramirez, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 292
Licensed in Texas since 2005, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
TX license M2763 (first issued 2005; active) -
Internal Medicine Physician
TX license M2763 (first issued 2005; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Certified Allergy and Asthma of San Antonio PA (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 292
- Services billed
- 10,647
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Professional service for preparation and provision of 1 or more antigens | 5,395 | 136 |
| Test for allergy using allergenic extract | 2,357 | 42 |
| Professional service for multiple injections of allergen | 1,459 | 106 |
| Professional service for single injection of allergen | 683 | 52 |
| Established patient office or other outpatient visit, 20-29 minutes | 359 | 235 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 72 | 12 |
| Test to measure expiratory airflow and volume | 63 | 53 |
| Injection of drug or substance under skin or into muscle | 48 | 41 |
| New patient office or other outpatient visit, 45-59 minutes | 45 | 45 |
| Injection, methylprednisolone acetate, 80 mg | 39 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azelastine Hcl Other prescribers in San Antonio, TX | 232 |
| Fluticasone Propionate Other prescribers in San Antonio, TX | 199 |
| Prednisone Other prescribers in San Antonio, TX | 90 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in San Antonio, TX | 80 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in San Antonio, TX | 77 |
| Montelukast Sodium Other prescribers in San Antonio, TX | 62 |
| Ipratropium Bromide Other prescribers in San Antonio, TX | 57 |
| Azithromycin Other prescribers in San Antonio, TX | 56 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in San Antonio, TX | 35 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in San Antonio, TX | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 138 payments worth $10,156 in total to this clinician.
| GlaxoSmithKline, LLC. | $3,806 |
|---|---|
| Genzyme Corporation | $2,678 |
| Novartis Pharmaceuticals Corporation | $1,114 |
| AstraZeneca Pharmaceuticals LP | $931 |
| Ars Pharmaceuticals Operations, Inc. | $289 |
| Regeneron Healthcare Solutions, Inc. | $272 |
| Csl Behring | $171 |
| Sanofi-aventis U.S. LLC | $140 |
| Food and Beverage | $5,012 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $2,600 |
| Consulting Fee | $1,446 |
| Travel and Lodging | $1,074 |
| Education | $25.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) NUCALA · IMMUNOLOGY | $2,600 |
| Genzyme Corporation Apr 8, 2025 | Consulting Fee | $1,446 |
| GlaxoSmithKline, LLC. Jun 13, 2025 | Travel and Lodging NUCALA · IMMUNOLOGY · travel to McAllen, TX | $353 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging Rhapsido · Immunology · travel to Chicago, IL · in-kind | $327 |
| Novartis Pharmaceuticals Corporation Sep 26, 2025 | Travel and Lodging Rhapsido · Immunology · travel to Chicago, IL · in-kind | $198 |
| GlaxoSmithKline, LLC. May 15, 2025 | Travel and Lodging NUCALA · IMMUNOLOGY · travel to McAllen, TX · in-kind | $196 |
| Ionis Pharmaceuticals, Inc. Sep 17, 2025 | Education in-kind | $25.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $155,927 in research payments for these studies, mostly to the institutions running them.
- A multicentre, randomized, double-blind, placebo-controlled, dose find
GlaxoSmithKline, LLC. - Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Genzyme Corporation · Active, not recruiting · NCT05097287 - A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma
AstraZeneca Pharmaceuticals LP - A 52-week, randomised, double-blind, double-dummy, parallel group, mul
GlaxoSmithKline, LLC. - A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participan…
AstraZeneca Pharmaceuticals LP - A multi-centre, single arm, open-label extension study to evaluate the
GlaxoSmithKline, LLC. - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.